Cytomel (Liothyronine) Cost in Nebraska 2026

What Does Liothyronine Actually Cost in Nebraska Right Now?

Generic liothyronine tablets cost about $35 per month at Nebraska retail pharmacies in 2026 when paying cash, making it one of the more accessible thyroid medications on the market. Brand-name Cytomel carries a Pfizer list price near $120 per month, but most patients never pay that figure because generic substitution is standard practice.

Liothyronine is the synthetic form of triiodothyronine (T3), the more metabolically active of the two main thyroid hormones. It differs from the far more commonly prescribed levothyroxine (T4) in that it does not require peripheral conversion to become active. The FDA approved Cytomel decades ago, and the drug remains listed on the FDA's approved drug database for hypothyroidism and pituitary thyroid-stimulating hormone suppression [1].

Price variation across Nebraska is real. A 30-tablet supply of 25 mcg generic liothyronine can range from roughly $20 at warehouse club pharmacies (Costco, Sam's Club) to $55 at independent pharmacies in smaller Nebraska towns without strong generic contract pricing. GoodRx and similar discount platforms frequently bring that range down to $18, $30 at Walgreens, CVS, and Hy-Vee locations statewide. The difference between the lowest and highest cash price for the same product in the same state can exceed 100%, so checking at least two pharmacies before filling makes financial sense [2].

Pfizer's manufacturer savings card for Cytomel may reduce out-of-pocket costs for commercially insured patients, but the card cannot be used with any federal or state government insurance program, including Nebraska Medicaid or Medicare Part D. Terms change annually; patients should confirm eligibility directly at the Pfizer patient savings portal before assuming a discount applies.

The 2026 figures above reflect aggregated retail survey data from Nebraska pharmacies cross-referenced against publicly available pricing databases. Actual cost at a specific pharmacy depends on tablet strength (5 mcg, 25 mcg, or 50 mcg), quantity dispensed, and any active discount codes applied at the point of sale [3].

Does Nebraska Medicaid Cover Liothyronine?

Nebraska Medicaid does not cover Cytomel or generic liothyronine for hypothyroidism adjunct therapy as of 2026. The state's preferred drug list prioritizes levothyroxine as the sole covered thyroid-replacement agent for most beneficiaries.

Nebraska's Medicaid pharmacy benefit is administered through the Nebraska Department of Health and Human Services and follows a preferred drug list (PDL) updated quarterly. Levothyroxine sodium (generic T4) sits on that PDL with no prior authorization required. Liothyronine does not appear on the PDL for routine hypothyroidism, which means the drug is either non-covered or requires an approved prior authorization exception demonstrating medical necessity [4].

Prior authorization for liothyronine under Nebraska Medicaid is theoretically possible but rarely approved. A prescriber would need to document that levothyroxine monotherapy was tried and failed to achieve symptomatic control, supported by labs and clinical notes. Even then, approval is not guaranteed. The American Thyroid Association's 2014 guidelines note that combination T4/T3 therapy "cannot be recommended as a general replacement for levothyroxine monotherapy" based on current evidence, which gives state Medicaid programs justification to restrict coverage [5].

For Medicaid beneficiaries who need liothyronine, the practical options are the manufacturer savings card (if they also hold commercial coverage), generic cash-pay pricing at $35/month, or a licensed 503A compounding pharmacy offering compounded T3 at roughly $40/month. Nebraska Medicaid does not cover compounded medications for thyroid replacement either.

Nebraska residents enrolled in Medicare Part D face similar restrictions. Liothyronine is a Tier 3 or Tier 4 drug on most Part D formularies, which can mean $40, $90 in cost-sharing per month even with coverage. Patients over 65 should verify their specific plan's formulary at Medicare.gov before assuming coverage exists.

Is Compounded Liothyronine Legal in Nebraska?

Compounded liothyronine T3 is legal in Nebraska when prepared by a licensed 503A pharmacy operating under a valid patient-specific prescription. No state law currently bans compounded thyroid preparations, and several compounding pharmacies in Omaha, Lincoln, and other Nebraska cities offer this service.

The federal framework matters here. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare customized drug preparations for individual patients with a valid prescription, provided they do not compound drugs that are essentially copies of commercially available products [6]. Because commercially available liothyronine comes only in three fixed strengths (5 mcg, 25 mcg, 50 mcg), a compounding pharmacy can argue that a non-standard dose (e.g., 10 mcg or 15 mcg) represents a clinically distinct formulation, not a copy.

Nebraska's Board of Pharmacy licenses and inspects compounding pharmacies under the Nebraska Pharmacy Practice Act. Pharmacies must maintain USP <795> compliance for non-sterile preparations. Patients should ask any pharmacy they consider whether it holds current Nebraska Board of Pharmacy licensure and has passed a recent inspection.

Compounded liothyronine costs roughly $40/month in Nebraska, slightly more than generic retail tablets. The clinical rationale for compounding is dose flexibility, not cost reduction. Some practitioners prefer compounded slow-release T3 capsules to blunt the sharp absorption peak that standard tablets produce, though the clinical evidence for slow-release T3 formulations is mixed [7]. Bunevicius et al. (NEJM, 1999) demonstrated that partial T4-to-T3 substitution (replacing 50 mcg levothyroxine with 12.5 mcg liothyronine) improved mood and neuropsychological function compared with levothyroxine alone in a crossover study of 33 patients, suggesting a physiological role for exogenous T3 in some individuals [8].

The FDA does not currently prohibit the compounding of liothyronine under 503A, but enforcement priorities can shift. Patients and prescribers should monitor FDA communications for any changes to the list of drugs that cannot be compounded [9].

Which Insurance Plans Cover Liothyronine in Nebraska?

Most private insurance plans in Nebraska cover generic liothyronine at Tier 2 or Tier 3, with copays ranging from $10 to $45 per month after the deductible is met. Brand Cytomel coverage is less consistent and typically requires step therapy through the generic first.

Nebraska residents obtain private insurance primarily through employer-sponsored plans, the ACA marketplace (HealthCare.gov), and individual policies. Among ACA marketplace plans available in Nebraska in 2026, all metal-tier plans (Bronze through Platinum) must cover prescription drugs as an essential health benefit. Liothyronine appears on most formularies because it is an established, inexpensive generic. The question is which tier and what cost-sharing applies [10].

Typical tier placement for generic liothyronine across Nebraska commercial plans:

• Tier 1 (preferred generic): $5, $15 copay. Found on some BCBS Nebraska, Medica, and UnitedHealthcare plans.
• Tier 2 (non-preferred generic): $20, $35 copay. More common when the plan has a preferred T4 alternative.
• Tier 3 (preferred brand or specialty): $40, $60 copay. Applies to brand Cytomel on plans that cover it at all.

Step therapy requirements are common. A plan may require documented failure on levothyroxine before approving liothyronine, mirroring the clinical guideline preference for T4 monotherapy as first-line treatment for hypothyroidism [11]. Patients who have already tried levothyroxine and experienced residual symptoms should have their prescriber submit supporting documentation at the time of the prior authorization request to avoid unnecessary delays.

The Endocrine Society's 2019 Clinical Practice Guideline on hypothyroidism states: "We suggest a trial of combination T4 and T3 therapy in hypothyroid patients who have persistent symptoms despite optimal levothyroxine therapy" [12]. That language gives prescribers a defensible evidence base for prior authorization appeals when a commercial insurer denies liothyronine coverage.

Patients with high-deductible health plans (HDHPs) paired with a Health Savings Account (HSA) can use HSA funds tax-free for liothyronine purchases, including compounded preparations from 503A pharmacies. This effectively reduces the after-tax cost by the patient's marginal income tax rate.

How Nebraska Telehealth Prescribing Works for Liothyronine

Nebraska law permits telehealth prescribing of liothyronine without requiring an in-person visit first, provided the prescriber conducts a clinically adequate evaluation, reviews relevant lab work, and establishes a valid patient-prescriber relationship.

Nebraska's telehealth statute (Neb. Rev. Stat. § 71-8505) does not mandate an in-person encounter prior to prescribing for most non-controlled substances. Liothyronine is not a controlled substance under either federal law or Nebraska state law, so the full telehealth prescribing framework applies [13]. A licensed Nebraska physician, APRN, or PA can initiate liothyronine therapy via a synchronous audio-video encounter after reviewing thyroid function labs (TSH, Free T4, and ideally Free T3).

The HealthRX clinical team evaluates telehealth liothyronine candidates using a three-step protocol:

1. Lab review. Current TSH, Free T4, Free T3, and thyroid antibody panel (anti-TPO, anti-thyroglobulin). Labs must be dated within 90 days.
2. Symptom burden assessment. Patients complete a validated thyroid symptom score (ThyST or equivalent) to document residual symptoms despite T4 therapy.
3. Dose titration plan. Starting dose is typically 5 to 25 mcg/day, with follow-up labs at 6 to 8 weeks. No patient starts above 25 mcg/day without prior T3 therapy history.

This framework matters because liothyronine has a narrower therapeutic index than levothyroxine. The American Association of Clinical Endocrinology (AACE) notes that T3 levels can rise sharply after dosing, potentially stressing cardiac tissue in susceptible patients, particularly those over 60 or with pre-existing atrial fibrillation [14]. Telehealth prescribing does not reduce this clinical risk; it just shifts where the conversation happens.

Follow-up labs are non-negotiable regardless of whether the visit is in-person or virtual. Patients who believe they can self-direct T3 dosing based on symptoms alone, without periodic TSH and Free T3 monitoring, face real harm potential. The thyroid axis does not self-report accurately through symptoms at every point along the dose-response curve [15].

The Cheapest Way to Get Liothyronine in Nebraska

The cheapest verified path to liothyronine in Nebraska in 2026 is a GoodRx coupon applied to a 90-day supply of generic 25 mcg tablets at a high-volume pharmacy, which can bring the monthly equivalent cost below $20.

Breaking this down by option:

Generic + GoodRx at chain pharmacy. A 90-day supply (270 tablets of 25 mcg generic liothyronine) using a GoodRx Gold code at Walgreens or Hy-Vee locations in Omaha or Lincoln has been confirmed at $52, $60 total, or roughly $17, $20/month. This beats the $35/month average retail cash price by a wide margin [16].

Warehouse club pharmacy. Costco (Omaha) does not require membership to use the pharmacy. Its generic pricing on liothyronine 25 mcg 90-count runs approximately $14, $22 without any coupon, making it competitive with GoodRx at chain stores.

Mail-order pharmacy. Commercial insurance members can often get a 90-day supply at a lower per-month copay through a plan's mail-order benefit. Members of BCBS Nebraska and UnitedHealthcare should check their plan's mail-order option through OptumRx or Express Scripts.

Mark Cuban's Cost Plus Drugs (CostPlusDrugs.com). As of early 2025, liothyronine 25 mcg (90 tablets) was listed at $10.60 plus a $5 dispensing fee and $5 shipping, totaling roughly $21 for a 90-day supply. Nebraska residents can use this service. The prescription must be sent directly to Cost Plus; it cannot be processed through insurance [17].

Compounded T3. At $40/month, compounded liothyronine costs more than the cheapest generic options. It makes sense only when a non-standard dose or formulation is clinically required, not as a cost-saving measure.

Patients should never purchase liothyronine from non-US online sources. The FDA has issued repeated warnings about counterfeit and subpotent thyroid hormone products sold through unverified international websites, and such purchases are illegal under federal law [18].

Understanding Liothyronine Dosing and Why It Affects Total Cost

Dose strength directly affects cost. A patient taking 50 mcg/day will spend more than one taking 25 mcg/day, both because more tablets are consumed and because higher-strength tablets may carry a different unit price.

Standard liothyronine dosing for combination T4/T3 therapy begins at 5 to 25 mcg of T3 daily, often split into two doses to smooth the pharmacokinetic curve. The drug's plasma half-life is approximately 1 day, considerably shorter than levothyroxine's 7-day half-life. This short half-life explains why some clinicians split the daily T3 dose into morning and midday administrations to avoid the afternoon energy dip some patients report [19].

The NEJM landmark study by Bunevicius et al. (1999, N=33) used a substitution of 12.5 mcg liothyronine for 50 mcg levothyroxine. Patients in the T4/T3 arm showed statistically significant improvements in 17 of 19 neuropsychological measures compared with levothyroxine monotherapy (P<0.05 for most measures) [8]. Later replication studies produced more mixed results, but this trial remains the most cited evidence for T3 combination therapy and is referenced in both ATA and Endocrine Society guidelines [5].

At the 12.5 mcg/day dose used in Bunevicius et al., a patient splitting tablets from a 25 mcg tablet supply would consume one 25 mcg tablet every two days, effectively halving monthly tablet consumption. This approach can reduce cost to as little as $10/month with discount pricing, though tablet splitting requires a pillcutter and consistent technique to maintain dose accuracy. Patients should not split liothyronine tablets without explicit prescriber guidance, as uneven splitting can create clinically meaningful dose variation [20].

Nebraska Discount Programs and Patient Assistance for Liothyronine

Several discount mechanisms are available to Nebraska residents beyond standard GoodRx coupons. Pfizer's patient assistance program (PAP) for Cytomel offers free or reduced-cost brand-name drug to qualifying low-income patients who meet income thresholds, typically at or below 400% of the federal poverty level.

To apply for Pfizer's PAP, patients must submit proof of income, a current prescription, and confirmation that they lack adequate prescription coverage. Applications are processed through the Pfizer RxPathways program. Processing typically takes 2 to 4 weeks, and medication is shipped to the prescriber's office or the patient's home depending on program logistics [21].

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain databases of patient assistance programs and can identify whether a Nebraska resident qualifies for any active programs covering liothyronine or Cytomel. Both databases are free to search.

Nebraska does not operate a state-run pharmaceutical assistance program comparable to those in Pennsylvania (PACE) or New Jersey (PAAD) that would supplement federal programs. Nebraska residents without insurance or Medicaid rely entirely on manufacturer PAPs, discount cards, and cash-pay pricing strategies outlined above.

The Nebraska 211 helpline (dial 2-1-1) can connect uninsured or underinsured residents with local health departments and federally qualified health centers (FQHCs) that may offer sliding-scale prescription assistance. FQHCs in Omaha (OneWorld Community Health), Lincoln (Community Health Endowment clinics), and Grand Island serve patients regardless of ability to pay and can sometimes access 340B pricing, which can bring drug costs well below standard retail [22].

340B pricing at FQHCs represents one of the least-publicized ways that low-income Nebraska patients can access liothyronine at below-market prices. The 340B program, administered by HRSA, requires drug manufacturers to offer outpatient drugs at significantly reduced prices to qualifying covered entities. A patient who receives care at an FQHC and fills their prescription through that clinic's in-house or contract pharmacy may pay a fraction of the retail cash price [23].